European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug
The EU’s Medicines Agency (EMA) rejects market authorisation for early intervention Alzheimer’s treatment Leqembi (lecanemab) due to concerns over side-effects.
The EU’s Medicines Agency (EMA) rejects market authorisation for early intervention Alzheimer’s treatment Leqembi (lecanemab) due to concerns over side-effects.